AUAUniversity American Urological Association

AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

CME Available: https://auau.auanet.org/node/41048

At the conclusion of this activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)
2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.
3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB
4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents
5. Discuss potential future pharmacological pathways and therapies for OAB.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas

Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) Webcast (2024)

CME Available: https://auau.auanet.org/node/41056

At the conclusion of this activity, participants will be able to:
1. Discuss the third-line therapies available to treat OAB refractory to conservative techniques.
2. Effectively provide counseling regarding advanced treatment techniques with "friendly, nonthreatening" language that does not intimidate the patients.
3. Consider helpful techniques to optimize lead placement for sacral neuromodulation and be comfortable with troubleshooting the device.
4. Incorporate caveats that are important in the delivery of injections in the bladder for treatment of OAB.
5. Incorporate peripheral nerve stimulation options, including the traditional and newer techniques that will be discuss in detail, into their practice as they see fit.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas

AUA2024: 003IC Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice

CME Available: https://auau.auanet.org/node/40976

At the conclusion of this activity, participants will be able to:
1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing.
2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability.
3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer.
4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Journal Club 101

Guest: Melissa Kaufman, MD, PHD, FACS

Outline:
Segment #1: History of peer review
Segment #2: Models of peer review
Segment #3: General review best practices
Segment #4: General structure for manuscript review
Segment #5: Granular aspects of manuscript review

BPH: Surgical Treatment

Guest: Bilal Chughtai, MD

Outline:
Segment #1: Bladder Health
Segment #2: Diagnostics
Segment #3: Stents
Segment #4: New MISTs

AUA2024: Surgical Laser Enucleation of the Prostate

Guests: Amy Krambeck, MD and Mark Assmus, MD

Outline:
Segment #1: Why Enucleation
Segment #2: What makes this course special?
Segment #3: What is new this year compared to last year?
Segment #4: What do you think makes this course unique?
Segment #5: Who is the ideal participant?